Factors Influencing Risk of Progression of Chronic Kidney Disease
FAIR-PROGRESS
1 other identifier
observational
1,300
1 country
1
Brief Summary
The aim of this study is to identify typical patterns of renal function evolution in patients with stage 4 chronic kidney disease, regularly followed in nephrology consultation and included in a French cohort.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2012
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 9, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2018
CompletedFirst Submitted
Initial submission to the registry
May 13, 2019
CompletedFirst Posted
Study publicly available on registry
May 17, 2019
CompletedMay 17, 2019
May 1, 2019
6.7 years
May 13, 2019
May 16, 2019
Conditions
Outcome Measures
Primary Outcomes (2)
Evolution of estimated Glomerular Filtration Rate (GFR) according to MDRD equation (modification of diet in renal disease) at each visit
up to 3 years
Time between inclusion and occurrence of the "progression" event
progression: initiation of an extra-renal purification technique or reduction of GFR of at least 5 mL / min / 1.73m2 compared to inclusion in FAIR-PROGRESS
up to 3 years
Eligibility Criteria
Adult population with chronic renal failure, before replacement therapy, followed in 9 nephrology departments of Bourgogne Franche-Comté.
You may qualify if:
- Patients included in the ND-CRIS cohort on the date when the estimate of their GFR is strictly less than 30mL/min/1.73m2 and greater than or equal to 15mL/min/1.73m2 (MDRD equation).
- Patients should have at least two measurements of GFR \<30mL/min/1.73m2 to be included, at least one of them greater than or equal to 15mL/min/1.73m2. The date of the first GFR \<30mL/min/ 1.73m2 will be considered as the date of origin.
You may not qualify if:
- Patients with GFR ≥30mL / min / 1.73m2 or \<15mL / min / 1.73m2
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Centre Hospitalier Universitaire de Besançon
Besançon, 25000, France
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 13, 2019
First Posted
May 17, 2019
Study Start
April 9, 2012
Primary Completion
December 31, 2018
Study Completion
December 31, 2018
Last Updated
May 17, 2019
Record last verified: 2019-05